Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
Rishi Patel(Texas Tech University), Marianna Fontana(Amyloidosis Foundation), Daniel Knight(University College London), Aviva Petrie(Eastman Dental Hospital), Dorota Rowczenio(Children's Cancer and Leukaemia Group), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Liza Chacko(Imperial College London), Gianfranco Sinagra(Società Italiana di Cardiologia), Francesco Bandera(IRCCS Policlinico San Donato), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Charlotte Manisty(National Institutes of Health), Janet A. Gilbertson(The Royal Free Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Ambra Masi(MACOM (United States)), Carol Whelan(The Royal Free Hospital), Kiara N. Patel(University College London), Ashutosh Wechalekar(University College Hospital), Yousuf Razvi(The Royal Free Hospital), Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Tushar Kotecha(Royal Society), Adam Ioannou(The Royal Free Hospital), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), James Moon(University of Michigan)
Cited by 94
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Truncations of Titin Causing Dilated Cardiomyopathy
|New England Journal of Medicine|2012|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k